mibe GmbH Arzneimittel reposted this
Dermapharm continues its growth strategy! Our preliminary full year results for fiscal year 2023 have been published today: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business >> Consolidated revenue grows by 10.8% compared to previous year to a record EUR 1.1 bn >> Adjusted consolidated EBITDA of EUR 310.2m resulting in an adjusted consolidated EBITDA margin of 27.3% >> Board of Management proposes dividend of EUR 0.88 per share at Annual General Meeting >> Strengthening of “Other Healthcare products” segment >> Further revenue and EBITDA growth expected in 2024 You can also find the Corporate News in German and English on our website: https://lnkd.in/e6eDwaUK
